Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-03 7:43 pm Purchase |
2025-01-30 | 13G | Applied Therapeutics, Inc. APLT |
Venrock Healthcare Capital Partners III L.P. | 5,012,796 10.100% |
5,012,796 (New Position) |
Filing History |
| 2024-11-14 4:00 pm Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
TANG CAPITAL MANAGEMENT, LLC | 4,321,547 9.990% |
4,321,547 (New Position) |
Filing History |
| 2024-11-14 3:57 pm Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
SUVRETTA CAPITAL MANAGEMENT, LLC | 4,328,904 9.990% |
1,644,899 (+61.29%) |
Filing History |
| 2024-11-14 12:02 pm Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Vestal Point Capital, LP | 4,000,000 9.300% |
4,000,000 (New Position) |
Filing History |
| 2024-11-13 12:54 pm Purchase |
2024-11-07 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Capital World Investors | 3,374,064 7.800% |
3,374,064 (New Position) |
Filing History |
| 2024-11-12 4:05 pm Unchanged |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
The Vanguard Group | 2,150,527 4.970% |
0 (Unchanged) |
Filing History |
| 2024-11-12 09:31 am Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Adage Capital Management L.P. | 1,419,792 3.290% |
1,419,792 (New Position) |
Filing History |
| 2024-11-07 2:34 pm Purchase |
2024-11-05 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 4,887,867 10.000% |
1,200,000 (+32.54%) |
Filing History |
| 2024-11-04 12:00 pm Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
The Vanguard Group | 2,150,527 4.970% |
369,108 (+20.72%) |
Filing History |
| 2024-04-01 4:14 pm Sale |
2024-03-28 | 13D | KalVista Pharmaceuticals, Inc. KALV |
TCG Crossover GP I, LLC | 1,345,826 3.200% |
-1,355,014 (-50.17%) |
Filing History |
| 2024-02-26 4:35 pm Purchase |
2024-02-15 | 13G | KalVista Pharmaceuticals, Inc. KALV |
ADAGE CAPITAL PARTNERS GP L.L.C. | 2,845,000 6.870% |
2,845,000 (New Position) |
Filing History |
| 2024-02-22 1:22 pm Purchase |
2024-02-20 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 3,687,867 8.900% |
105,573 (+2.95%) |
Filing History |
| 2024-02-20 4:49 pm Sale |
2024-02-07 | 13D | KalVista Pharmaceuticals, Inc. KALV |
TCG Crossover GP I, LLC | 2,700,840 6.520% |
-707,241 (-20.75%) |
Filing History |
| 2024-02-14 8:52 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III L.P. | 4,824,731 14.000% |
1,251,017 (+35.01%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
TANG CAPITAL PARTNERS LP | 3,440,345 9.960% |
243,899 (+7.63%) |
Filing History |
| 2024-02-13 5:19 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,684,005 7.800% |
887,626 (+49.41%) |
Filing History |
| 2024-02-13 5:07 pm Purchase |
2023-12-29 | 13G | KalVista Pharmaceuticals, Inc. KALV |
The Vanguard Group | 1,781,419 5.150% |
1,781,419 (New Position) |
Filing History |
| 2024-02-12 8:30 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Saturn V Capital Management LP | 1,431,259 4.100% |
1,431,259 (New Position) |
Filing History |
| 2024-02-09 09:16 am Sale |
2024-02-08 | 13G | KalVista Pharmaceuticals, Inc. KALV |
FMR LLC | 50,970 0.147% |
-1,260,032 (-96.11%) |
Filing History |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
BlackRock Inc. BLK |
2,242,025 6.500% |
669,604 (+42.58%) |
Filing History |